Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
Mucosal melanoma is a rare disease epidemiologically and molecularly distinct from cutaneous melanoma developing from melanocytes located in mucosal membranes. Little is known about its therapy. In this paper, we aimed to evaluate the results of immunotherapy and radiotherapy in a group of patients...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/11/3131 |
| _version_ | 1797549769962291200 |
|---|---|
| author | Pawel Teterycz Anna M. Czarnecka Alice Indini Mateusz J. Spałek Alice Labianca Pawel Rogala Bożena Cybulska-Stopa Pietro Quaglino Umberto Ricardi Serena Badellino Anna Szumera-Ciećkiewicz Slawomir Falkowski Mario Mandala Piotr Rutkowski |
| author_facet | Pawel Teterycz Anna M. Czarnecka Alice Indini Mateusz J. Spałek Alice Labianca Pawel Rogala Bożena Cybulska-Stopa Pietro Quaglino Umberto Ricardi Serena Badellino Anna Szumera-Ciećkiewicz Slawomir Falkowski Mario Mandala Piotr Rutkowski |
| author_sort | Pawel Teterycz |
| collection | DOAJ |
| description | Mucosal melanoma is a rare disease epidemiologically and molecularly distinct from cutaneous melanoma developing from melanocytes located in mucosal membranes. Little is known about its therapy. In this paper, we aimed to evaluate the results of immunotherapy and radiotherapy in a group of patients with advanced mucosal melanoma, based on the experience of five high-volume centers in Poland and Italy. There were 82 patients (53 female, 29 male) included in this retrospective study. The median age in this group was 67.5 (IQR: 57.25–75.75). All patients received anti-PD1 or anti-CTLA4 antibodies in the first or second line of treatment. Twenty-three patients received radiotherapy during anti-PD1 treatment. In the first-line treatment, the median progression-free survival (PFS) reached six months in the anti-PD1 group, which was statistically better than 3.1 months in the other modalities group (<i>p</i> = 0.004). The median overall survival (OS) was 16.3 months (CI: 12.1–22.3) in the whole cohort. Patients who received radiotherapy (RT) during the anti-PD1 treatment had a median PFS of 8.9 months (CI: 7.4–NA), whereas patients treated with single-modality anti-PD1 therapy had a median PFS of 4.2 months (CI: 3.0–7.8); this difference was statistically significant (<i>p</i> = 0.047). Anti-PD1 antibodies are an effective treatment option in advanced mucosal melanoma (MM). The addition of RT may have been beneficial in the selected subgroup of mucosal melanoma patients. |
| first_indexed | 2024-03-10T15:20:07Z |
| format | Article |
| id | doaj.art-cc194297a9f84be9aeb57fad9397457e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T15:20:07Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-cc194297a9f84be9aeb57fad9397457e2023-11-20T18:36:54ZengMDPI AGCancers2072-66942020-10-011211313110.3390/cancers12113131Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern ImmunotherapyPawel Teterycz0Anna M. Czarnecka1Alice Indini2Mateusz J. Spałek3Alice Labianca4Pawel Rogala5Bożena Cybulska-Stopa6Pietro Quaglino7Umberto Ricardi8Serena Badellino9Anna Szumera-Ciećkiewicz10Slawomir Falkowski11Mario Mandala12Piotr Rutkowski13Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandMelanoma Unit, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24127 Bergamo, ItalyDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandMelanoma Unit, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24127 Bergamo, ItalyDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandMaria Skłodowska-Curie National Research Institute—Oncology Center, Krakow Branch, 31-115 Krakow, PolandDepartment of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, ItalyDepartment of Oncology, Radiation Oncology, University of Turin, 10126 Turin, ItalyDepartment of Oncology, Radiotherapy Unit, AOU Città della Salute e della Scienza di Torino, 10126 Turin, ItalyDepartment of Pathology and Laboratory Medicine Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandMelanoma Unit, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24127 Bergamo, ItalyDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandMucosal melanoma is a rare disease epidemiologically and molecularly distinct from cutaneous melanoma developing from melanocytes located in mucosal membranes. Little is known about its therapy. In this paper, we aimed to evaluate the results of immunotherapy and radiotherapy in a group of patients with advanced mucosal melanoma, based on the experience of five high-volume centers in Poland and Italy. There were 82 patients (53 female, 29 male) included in this retrospective study. The median age in this group was 67.5 (IQR: 57.25–75.75). All patients received anti-PD1 or anti-CTLA4 antibodies in the first or second line of treatment. Twenty-three patients received radiotherapy during anti-PD1 treatment. In the first-line treatment, the median progression-free survival (PFS) reached six months in the anti-PD1 group, which was statistically better than 3.1 months in the other modalities group (<i>p</i> = 0.004). The median overall survival (OS) was 16.3 months (CI: 12.1–22.3) in the whole cohort. Patients who received radiotherapy (RT) during the anti-PD1 treatment had a median PFS of 8.9 months (CI: 7.4–NA), whereas patients treated with single-modality anti-PD1 therapy had a median PFS of 4.2 months (CI: 3.0–7.8); this difference was statistically significant (<i>p</i> = 0.047). Anti-PD1 antibodies are an effective treatment option in advanced mucosal melanoma (MM). The addition of RT may have been beneficial in the selected subgroup of mucosal melanoma patients.https://www.mdpi.com/2072-6694/12/11/3131mucosal melanomanivolumabpembrolizumabipilimumabradiotherapy |
| spellingShingle | Pawel Teterycz Anna M. Czarnecka Alice Indini Mateusz J. Spałek Alice Labianca Pawel Rogala Bożena Cybulska-Stopa Pietro Quaglino Umberto Ricardi Serena Badellino Anna Szumera-Ciećkiewicz Slawomir Falkowski Mario Mandala Piotr Rutkowski Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy Cancers mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy |
| title | Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy |
| title_full | Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy |
| title_fullStr | Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy |
| title_full_unstemmed | Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy |
| title_short | Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy |
| title_sort | multimodal treatment of advanced mucosal melanoma in the era of modern immunotherapy |
| topic | mucosal melanoma nivolumab pembrolizumab ipilimumab radiotherapy |
| url | https://www.mdpi.com/2072-6694/12/11/3131 |
| work_keys_str_mv | AT pawelteterycz multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT annamczarnecka multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT aliceindini multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT mateuszjspałek multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT alicelabianca multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT pawelrogala multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT bozenacybulskastopa multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT pietroquaglino multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT umbertoricardi multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT serenabadellino multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT annaszumeracieckiewicz multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT slawomirfalkowski multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT mariomandala multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy AT piotrrutkowski multimodaltreatmentofadvancedmucosalmelanomaintheeraofmodernimmunotherapy |